Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (AU:EBRDA) — Market Cap & Net Worth
Market Cap & Net Worth: Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA)
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (AU:EBRDA) has a market capitalization of $47.41 (AU$67.00) as of April 12, 2026. Listed on the AU stock exchange, this Australia-based company holds position #48016 globally and #1563 in its home market, demonstrating a 9.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's stock price AU$0.67 by its total outstanding shares 100 (100.00).
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement Market Cap History: 2026 to 2026
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's market capitalization history from 2026 to 2026. Data shows growth from $47.41 to $47.41 (0.00% CAGR).
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EBRDA by Market Capitalization
Companies near Cdi 10:1 Us Prohib Excl Qib Deferred Settlement in the global market cap rankings as of April 12, 2026.
Key companies related to Cdi 10:1 Us Prohib Excl Qib Deferred Settlement by market ranking:
- PT Merdeka Gold Resources Tbk (JK:EMAS): Ranked #48007 globally with a market cap of $47.61 USD ( Rp812.50K IDR).
- Detalion Games S.A. (WAR:DEG): Ranked #48008 globally with a market cap of $47.61 USD ( zł173.00 PLN).
- Cuulong Fish JSC (VN:ACL): Ranked #48017 globally with a market cap of $47.30 USD ( ₫1.25 Million VND).
- National Silk and Rayon Mills Limited (KAR:NSRM): Ranked #48018 globally with a market cap of $47.30 USD ( PKRs13.19K PKR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #48007 | PT Merdeka Gold Resources Tbk | JK:EMAS | $47.61 | Rp8125.00 |
| #48008 | Detalion Games S.A. | WAR:DEG | $47.61 | zł1.73 |
| #48017 | Cuulong Fish JSC | VN:ACL | $47.30 | ₫12450.00 |
| #48018 | National Silk and Rayon Mills Limited | KAR:NSRM | $47.30 | PKRs131.90 |
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement Historical Marketcap From 2026 to 2026
Between 2026 and today, Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's market cap moved from $47.41 to $ 47.41, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$47.41 | -- |
End of Day Market Cap According to Different Sources
On Apr 12th, 2026 the market cap of Cdi 10:1 Us Prohib Excl Qib Deferred Settlement was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.41 USD |
| MoneyControl | $47.41 USD |
| MarketWatch | $47.41 USD |
| marketcap.company | $47.41 USD |
| Reuters | $47.41 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cdi 10:1 Us Prohib Excl Qib Deferred Settlement
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization thera… Read more